Crossject S.A. (ALCJ.PA) Stock Analysis & Winston Score

Crossject is a French medical device company that makes a needle-free auto-injector called ZENEO. The device lets patients or emergency responders inject medicine quickly without using a needle — the drug is pre-loaded inside the device. Its main focus is on emergency medicines, such as treatments for seizures, severe allergic reactions, and opioid overdoses, targeting hospitals, military, and first responders. Crossject earns money by developing and eventually selling these pre-filled drug-device combination products, though it has not yet generated meaningful commercial revenue. The company is based in France and operates primarily in Europe, with ambitions to enter the U.S. market. It is a small, pre-revenue biotech-style company, which means it burns cash while waiting for regulatory approvals — the biggest risk is whether it can secure those approvals and find commercial partners before running out of funding.